This case report is jointly authored by US clinicians from leading hospitals, Houston Methodist Hospital, Weill Cornell Medical College and Johns Hopkins
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Based on the CRL, the STARGLO data do not provide sufficient evidence to support the proposed second-line DLBCL indication in the US patient population
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Godavari Biorefineries receives patent from CNIPA
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
The first project will focus on developing an AI-based platform for the sterically guided design of bispecific antibodies
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
The company showcased three core programs developed through this platform
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Subscribe To Our Newsletter & Stay Updated
